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Background: Vascular endothelial dysfunction (ED) is a recognized entity in patients with established Coronary Artery Disease (CAD). The role of 
HDL targeted therapies on ED is incompletely studied. Niacin has proven clinical benefit in patients with CAD, but its additive effect in patients with 
optimally treated LDL cholesterol is the subject of ongoing clinical trials. The effect of Niacin on endothelial function, in the presence of optimal LDL 
cholesterol is unclear.
Objectives: The objective of the study was to determine the effect of extended release (ER) niacin on endothelial and vascular function assessed 
by brachial ultrasound Flow-Mediated Dilatation (FMD), peak hyperemic velocity (VTI) and Pulse Arterial Tonometry (PAT) in patients with established 
CAD, already treated with high dose statins.
Methods: A total of 66 patients (mean age 57.9±8.5) had complete data and received ER niacin (1500 mg/d) and placebo in a randomized 
cross-over fashion for 3 months of each therapy. All patients received atorvastatin 80 mg/d. FMD, hyperemic VTI and PAT measurements were 
performed at baseline and after each treatment period.
Results: Patients demographics, dyslipidemia parameters and endothelial function measurements were similar between the groups at baseline. 
Treatment with niacin improved dyslipidemia parameters (LDL placebo 1.53±0.51 vs. niacin 1.30±0.43; p=0.009); HDL placebo 0.95±0.16 vs. 
niacin 1.11±0.22; p<0.001). However, we did not observe any improvement in endothelial function as assessed by FMD (placebo 6.08±4.86 vs. 
niacin 6.62±4.84; p=0.344), VTI (placebo 75.14±28.10 vs. niacin78.48±26.36; p=0.58) or PAT (placebo 1.8±0.42 vs. niacin 1.79±0.5; p=0.99).
Conclusion: Niacin as add-on treatment to high dose statins in patients with established CAD significantly improves lipid profile. However, these 
positive changes were not associated with improved conduit vessel endothelial or microvascular function.
